Novogene Europe, a multi-omics research services partner, today announced that it has expanded its single-cell RNA sequencing capabilities at its Cambridge Omics Center. This expansion brings single-cell sequencing workflows built around the 10x Genomics Chromium platform even closer to academic, biotech and biopharmaceutical researchers in the UK. The service builds on Novogene Europe’s established single-cell expertise, including existing capabilities in Germany, and combines expert project support, sequencing infrastructure, and bioinformatics analysis to enable researchers to derive deeper biological insights from complex samples and meet the growing demand for accessible single-cell transcriptomics.
This announcement follows the launch of the Untargeted Metabolomics service at Novogene Europe’s Cambridge Omics Center. This marks the next step in a broader phase of field enhancement. This further strengthens the Cambridge Omics Center as a UK hub for advanced multi-omics services and reflects Novogene Europe’s continued investment in local scientific capacity and customer support.
Novogene Europe’s Cambridge service will initially focus on 3′ gene expression using cells or nuclei, supported by GEM-X chemistry, high-throughput Illumina sequencing, and Novogene Europe’s bioinformatics expertise. Services include sample processing, quality control, library preparation, sequencing and comprehensive bioinformatics analysis to support research across oncology, immunology, neuroscience, stem cell biology, developmental biology, translational research, biomarkers and drug discovery.
By profiling gene expression at single-cell or mononuclear resolution, researchers can explore cellular heterogeneity, identify rare populations, and investigate how different cell types and states contribute to biological function. Beyond the new Cambridge capabilities, Novogene Europe’s broad portfolio includes single-cell immune profiling with 5′ gene expression, T-cell and B-cell receptor sequencing.
The launch, announced in Novogene’s 15th anniversary year, reflects Novogene Europe’s continued development as a multi-omics research services partner, building on the expansion of its regional capabilities starting with untargeted metabolomics and leveraging Novogene’s broader global reach and technical expertise.
“Single-cell sequencing helps researchers study complex biological systems at a level of detail that is difficult to achieve with bulk approaches alone.” Tingting Zhou, Vice President of Novogene Europe, said: “Expanding access to single cell sequencing workflows through the Cambridge Omics Center will strengthen local support for UK researchers working across fields such as oncology, immunology, neuroscience, developmental biology and translational research.”
This launch builds on Novogene Europe’s established single cell expertise and marks the next step in developing the Cambridge Omics Center as a hub for advanced multi-omics services. As Novogene celebrates its 15th anniversary, we are pleased to continue expanding our scientific capabilities and bioinformatics support available to researchers across Europe. ”
We are delighted that Novogene Europe continues to develop its capabilities at the TusPark Bioinnovation Center at Cambridge Science Park. The expansion of the Cambridge Omics Center’s single cell capabilities will further strengthen the local research infrastructure and support Cambridge’s growing community of academic, biotech and biopharmaceutical innovators. ”
Kevin (Zhuocun) Lin, Managing Director, TusPark Holdings UK
